SCHEMBL3396609

SCHEMBL3396609

CN1CCN(Cc2cc(N)ccn2)CC1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.41
PRMT5 O14744 1/20 0.36
WDR77 Q9BQA1 1/20 0.36
TLR7 Q9NYK1 1/20 0.36
KDM5C P41229 1/20 0.36
KDM4C Q9H3R0 1/20 0.36
CXCR4 P61073 1/20 0.36
SLC2A1 P11166 1/20 0.35
LMNA P02545 1/20 0.34
PIM1 P11309 2/20 0.34
HDAC8 Q9BY41 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C19 P33261 1/20 0.34
KMT2A Q03164 1/20 0.34
HRH1 P35367 1/20 0.34
TNKS O95271 1/20 0.34
PARP1 P09874 1/20 0.34
TNKS2 Q9H2K2 1/20 0.34
PDE7B Q9NP56 1/20 0.34
MCHR1 Q99705 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3396399 0.80 LMNA (0.51) KDM5CKDM4CCXCR4LMNACYP1A2
SCHEMBL4293256 0.80 PIK3CD (0.45) PIK3CDPRMT5WDR77TLR7SLC2A1
SCHEMBL27824924 0.76 F10 (0.36) PRMT5WDR77KDM5CKDM4CKMT2A
SCHEMBL3397140 0.75 SIGMAR1 (0.39) TLR7KDM5CKDM4CCXCR4LMNA
SCHEMBL14896745 0.75 CXCR4 (0.50) KDM5CKDM4CCXCR4LMNACYP1A2
SCHEMBL3398174 0.74 MAPK1 (0.56) PIK3CDTLR7LMNAHDAC8KMT2A
SCHEMBL28790316 0.74 KDM5C (0.36) KDM5CKDM4CCXCR4LMNACYP1A2
SCHEMBL3401709 0.74 LMNA (0.60) PIK3CDTLR7SLC2A1LMNAMCHR1
SCHEMBL28786467 0.73 KDM5C (0.41) KDM5CKDM4CCXCR4LMNACYP1A2
SCHEMBL3396892 0.73 GRIN2D (0.52) PIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420657-B2 Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors NOVARTIS AG (CH) 2013-04-16 US disclosed
EP-2247591-A1 PYRROLO [2, 3-D]PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS Novartis AG (CH) 2010-11-10 EP disclosed
US-20090203688-A1 HETEROCYCLIC COMPOUNDS NOVARTIS AG 2009-08-13 US disclosed
WO-2009098236-A1 PYRROLO [2, 3-D] PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS NOVARTIS AG (CH) 2009-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203688-A1 HETEROCYCLIC COMPOUNDS ABL1, JAK2, JAK1 PIK3CD 400/4885PRMT5 539/4885WDR77 3276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.